How should I manage a patient with poorly controlled anxiety and depression who is on buspirone 10 mg three times daily, clonazepam 0.25 mg twice daily, hydroxyzine 10 mg three times daily, mirtazapine 30 mg daily, gabapentin 400 mg three times daily, and has a history of alcoholism with four years of sobriety?

Management of Poorly Controlled Anxiety and Depression in Patient with History of Alcoholism

This patient requires immediate simplification and optimization of their polypharmacy regimen, with priority given to discontinuing clonazepam due to the history of alcoholism, optimizing the SSRI/SNRI therapy (which is notably absent), and cautiously continuing buspirone which has specific evidence for anxious patients with alcohol use disorder history.

Critical Medication Review and Concerns

Benzodiazepine Use in Alcohol Use Disorder History

The current regimen includes clonazepam 0.25 mg BID, which is problematic in a patient with 4 years of sobriety from alcoholism. Primary care guidelines explicitly recommend caution with benzodiazepines in patients with substance use disorders 1. Benzodiazepine dependence requires specialist referral or a slow taper over months in motivated patients without history of withdrawal seizures 1. Given the alcohol use disorder history, this patient is at higher risk for cross-dependence and relapse.

Absence of First-Line Antidepressants

Notably, this patient is on mirtazapine but lacks an SSRI or SNRI, which are first-line treatments for both anxiety and depression. The FDA labeling for mirtazapine emphasizes monitoring for worsening depression and suicidal ideation, particularly during initial treatment or dose changes 2. However, mirtazapine alone is insufficient for this level of comorbidity.

Excessive Polypharmacy Without Clear Benefit

The patient is on five psychotropic medications (buspirone, clonazepam, hydroxyzine, mirtazapine, gabapentin) yet remains poorly controlled, suggesting either inadequate dosing of effective agents or accumulation of marginally effective medications with side effects.

Evidence-Based Treatment Algorithm

Step 1: Initiate or Optimize SSRI/SNRI Therapy

Add sertraline (starting 25-50 mg daily, target 100-200 mg) or paroxetine as first-line treatment.

• Sertraline showed effectiveness in PTSD and comorbid anxiety-alcohol use disorder 3
• Paroxetine demonstrated superiority in social anxiety patients with alcohol dependence, with more than twice the global clinical response versus placebo (RR 2.23,95% CI 1.13-4.41) 4
• SSRIs require caution: they may increase alcohol consumption if the patient relapses to active drinking 3
• Escitalopram is an alternative first-line option for GAD in this population 5

Step 2: Taper and Discontinue Clonazepam

Begin a slow benzodiazepine taper over 2-3 months while establishing the SSRI:

• Reduce clonazepam by 0.125 mg every 1-2 weeks
• Monitor for increased anxiety, depression, seizures, and altered mental status 1
• This patient appears motivated (4 years sober) and has no documented seizure history, making outpatient taper feasible
• Critical pitfall: Abrupt discontinuation risks withdrawal seizures and relapse to alcohol use

Step 3: Continue Buspirone - Specific Evidence for This Population

Maintain buspirone 10 mg TID (consider increasing to 15 mg TID if tolerated):

• Buspirone has specific evidence in anxious alcoholics: it improved treatment retention, reduced anxiety, slowed return to heavy drinking, and reduced drinking days at 6-month follow-up 6
• Meta-analysis confirmed positive effects on treatment retention and anxiety in alcoholism treatment 7
• In recently detoxified alcoholics with GAD, buspirone was superior to placebo as anxiolytic and reduced days desiring alcohol 8
• Buspirone has a favorable safety profile with no interaction with alcohol 7
• Maximal effect achieved at 12 weeks with maintenance to 24 weeks 4

Step 4: Reassess Gabapentin and Hydroxyzine

Gabapentin 400 mg TID may be continued as it has evidence for comorbid anxiety-alcohol use disorder 3, though primarily studied for alcohol use itself.

Hydroxyzine 10 mg TID should be tapered and discontinued once SSRI is therapeutic (4-6 weeks):

• Hydroxyzine requires caution in anxiety treatment 5
• Provides only symptomatic relief without addressing underlying pathophysiology
• Contributes to polypharmacy burden

Step 5: Optimize Mirtazapine Dosing

Continue mirtazapine 30 mg at bedtime for now, but reassess after SSRI reaches therapeutic effect:

• Mirtazapine has some supportive evidence for anxiety but is low priority 5
• May provide benefit for comorbid depression and insomnia
• FDA warning: Monitor closely for worsening depression, suicidal thoughts, especially with dose changes 2
• Consider whether this can be discontinued once SSRI is optimized to reduce polypharmacy

Monitoring and Follow-Up Schedule

Weeks 1-4 (Initiation Phase):

• Start SSRI (sertraline or paroxetine)
• Begin slow clonazepam taper
• Weekly visits to monitor for:
  • Suicidal ideation (increased risk with antidepressants in adults <25 years, though less relevant if patient is older) 2
  • Benzodiazepine withdrawal symptoms
  • Alcohol craving or use
  • Serotonin syndrome risk (given buspirone + SSRI combination) 2

Weeks 4-12 (Optimization Phase):

• Continue clonazepam taper to completion
• Titrate SSRI to therapeutic dose
• Expect maximal buspirone effect by week 12 4
• Begin tapering hydroxyzine once SSRI therapeutic
• Biweekly visits

Weeks 12-24 (Maintenance Phase):

• Reassess need for all medications
• Consider simplifying to SSRI + buspirone ± gabapentin
• Monitor for sustained anxiety/depression control
• Monthly visits

Critical Safety Considerations

Serotonin Syndrome Risk

The combination of SSRI + buspirone + mirtazapine creates moderate serotonin syndrome risk 2. Monitor for: agitation, tachycardia, hyperthermia, tremor, hyperreflexia, GI symptoms. This risk is manageable with appropriate monitoring but requires patient education.

Agranulocytosis with Mirtazapine

Rare but serious: if patient develops sore throat, fever, stomatitis, or infection signs, obtain WBC count immediately and discontinue mirtazapine if neutropenia present 2.

Alcohol Relapse Risk

SSRIs may increase alcohol consumption if patient relapses to active drinking 3. Emphasize continued sobriety support and monitor alcohol use closely.

Angle-Closure Glaucoma

Antidepressants including mirtazapine and SSRIs may trigger angle-closure attack in susceptible patients 2. Screen for narrow angles if not previously evaluated.

Why Combined Therapy Works in This Population

Treatment should start early and target both pathologies simultaneously since anxiety disorders and alcohol use disorders reinforce each other 3. The evidence supports:

• CBT plus pharmacotherapy shows small but significant benefits over usual care plus pharmacotherapy (g=0.18 for frequency outcomes, g=0.28 for quantity outcomes) 9
• Recommend concurrent behavioral therapy/relapse prevention alongside medication optimization
• Women are particularly vulnerable to maintaining alcohol consumption with untreated anxiety 3

What NOT to Do

• Do not continue indefinite polypharmacy without reassessment
• Do not abruptly stop benzodiazepines - taper slowly over months
• Do not rely on hydroxyzine as primary anxiety treatment - it's adjunctive at best
• Do not use benzodiazepines long-term in patients with substance use disorder history
• Do not delay SSRI/SNRI initiation - these are first-line, evidence-based treatments